zanubrutinib

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of…

There is little question that the development of Bruton tyrosine kinase (BTK) inhibitors has changed the treatment landscape for Waldenström macroglobulinemia patients and their…

Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory…